Sugi Predict

Sugi Predict / Compounds / SCHEMBL269663

SCHEMBL269663

SCHEMBL269663

CCCC(=O)CC(C)(C)C

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CES2 O00748 3/20 0.43
▸ CES1 P23141 3/20 0.43
▸ HDAC3 O15379 4/20 0.42
▸ HDAC1 Q13547 4/20 0.42
▸ HDAC2 Q92769 4/20 0.42
▸ HDAC8 Q9BY41 4/20 0.42
▸ HDAC6 Q9UBN7 1/20 0.42
▸ FFAR3 O14843 3/20 0.41
▸ TSHR P16473 1/20 0.39
▸ ALDH1A1 P00352 2/20 0.38
▸ CTSD P07339 1/20 0.35
▸ TDP1 Q9NUW8 1/20 0.33
▸ PLA2G4A P47712 1/20 0.32
▸ HMGCR P04035 1/20 0.32
▸ CHRM1 P11229 1/20 0.32
▸ TBXA2R P21731 1/20 0.32
▸ ADRA1A P35348 1/20 0.32
▸ NPC1 O15118 1/20 0.32
▸ HPGD P15428 1/20 0.32
▸ RAB9A P51151 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14318586 0.87 HDAC3 (0.42) CES2CES1HDAC3HDAC1HDAC2
SCHEMBL12425764 0.84 CES1 (0.48) CES2CES1TSHRALDH1A1TDP1
SCHEMBL28875311 0.83 CES2 (0.43) CES2CES1HDAC3HDAC1HDAC2
SCHEMBL23824840 0.81 CES2 (0.41) CES2CES1HDAC3HDAC1HDAC2
SCHEMBL8836632 0.80 HMGCR (0.37) CES2CES1HDAC3HDAC1HDAC2
SCHEMBL4451253 0.80 KMT2A (0.56) CES2CES1TSHRALDH1A1TDP1
SCHEMBL8897012 0.80 KMT2A (0.56) CES2CES1TSHRALDH1A1TDP1
SCHEMBL11038929 0.80 KMT2A (0.56) CES2CES1TSHRALDH1A1TDP1
SCHEMBL19617979 0.80 KMT2A (0.56) CES2CES1TSHRALDH1A1TDP1
SCHEMBL15393198 0.80 KMT2A (0.56) CES2CES1TSHRALDH1A1TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 125 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2018152759-A1 STRETCHABLE CONDUCTIVE PASTE COMPOSITION E. I. DU PONT DE NEMOURS AND COMPANY (US) 2018-08-30 — — WO claimed
US-7704929-B2 Diaromatic amine derivatives as antioxidants CHEMTURA CORPORATION (US) 2010-04-27 — — US claimed
US-20070155633-A1 Diaromatic amine derivatives as antioxidants LANXESS SOLUTIONS US INC. 2007-07-05 — — US claimed
EP-1276804-B1 LIQUID ANTIOZONANTS AND RUBBER COMPOSITIONS CONTAINING SAME UNIROYAL CHEM CO INC (US) 2006-06-14 — — EP claimed
US-20050282878-A1 Process for the purification of fluconazole GLENMARK PHARMACEUTICALS LIMITED (IN) 2005-12-22 — — US claimed
US-6706216-B1 REACTION PRODUCT OF CATALYTIC REDUCTIVE ALKYLATION OF P-PHENYLENEDIAMINE OR DERIVATIVE WITH ACETONE AND SECOND CARBONYL COMPOUND UNIROYAL CHEMICAL COMPANY, INC. 2004-03-16 — — US claimed
US-6706217-B2 OBTAINED FROM THE REACTION OF A PARAPHENYLENEDIAMINE COMPOUND WITH ACETONE AND AT LEAST ONE OF KETONES AND ALDEHYDES, USING A REDUCTIVE ALKYLATION CATALYST UNIROYAL CHEMICAL COMPANY, INC. 2004-03-16 — — US claimed
EP-1276804-A1 LIQUID ANTIOZONANTS AND RUBBER COMPOSITIONS CONTAINING SAME Uniroyal Chemical Company, Inc. (US) 2003-01-22 — — EP claimed
US-20020061946-A1 Liquid antiozonants and rubber compositions containing same ADDIVANT USA, LLC 2002-05-23 — — US claimed
WO-2001081459-A1 LIQUID ANTIOZONANTS AND RUBBER COMPOSITIONS CONTAINING SAME UNIROYAL CHEMICAL COMPANY, INC. (US) 2001-11-01 — — WO claimed
US-20260132232-A1 OPHTHALMIC DEVICES BAUSCH LOMB IRELAND LTD (IE) 2026-05-14 — — US disclosed
EP-3788084-B1 OPHTHALMIC DEVICES CONTAINING UV BLOCKER AND METHODS FOR THEIR PREPARATION BAUSCH & LOMB (US) 2026-04-29 — — EP disclosed
US-12552883-B2 Ophthalmic devices BAUSCH + LOMB IRELAND LIMITED (IE) 2026-02-17 — — US disclosed
EP-4677398-A1 CONTACT LENS CONTAINING DEPROTECTED ULTRAVIOLET BLOCKERS Bausch + Lomb Ireland Limited (IE) 2026-01-14 — — EP disclosed
EP-4646240-A1 BIOMEDICAL DEVICES HAVING A SURFACE COATING Bausch + Lomb Ireland Limited (IE) 2025-11-12 — — EP disclosed
EP-0535057-A1 PROCESS FOR THE PREPARATION OF KETOXIMES EASTMAN CHEMICAL COMPANY (US) 1993-04-07 — — EP disclosed
WO-1991018867-A1 PROCESS FOR THE PREPARATION OF KETOXIMES EASTMAN KODAK COMPANY (US) 1991-12-12 — — WO disclosed
US-4900868-A Process for producing N,N'-disubstituted paraphenylene diamine mixtures by sequential reductive alkylation MONSANTO COMPANY (US) 1990-02-13 — — US disclosed
EP-0310321-A2 Immunomodulatory azaspiranes SMITHKLINE BEECHAM CORPORATION (US) 1989-04-05 — — EP disclosed
EP-0084527-A2 Process for producing paraphenylenediamine mixtures MONSANTO COMPANY (US) 1983-07-27 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050282878-A1 Process for the purification of fluconazole ERG28, CYP51A1, MAN2B1 CES2 811/4885CES1 1041/4885HDAC3 3141/4885
US-20260132232-A1 OPHTHALMIC DEVICES MYO1G, CRY1, UACA CES2 3730/4885CES1 1624/4885HDAC3 1068/4885
US-20070155633-A1 Diaromatic amine derivatives as antioxidants C9, C5, C1S CES2 1378/4885CES1 1483/4885HDAC3 1224/4885
US-12552883-B2 Ophthalmic devices ILK, MYLK, SMAD2 CES2 4234/4885CES1 3213/4885HDAC3 1249/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.